

## **ADVANCEMENTS IN SUSTAINED RELEASE DRUG DELIVERY SYSTEMS: DESIGN PRINCIPLES, FORMULATION STRATEGIES AND NOVEL APPROACHES**

**Kunwar Abdul Kalam<sup>1\*</sup> and Suneel Kumar Niranjan<sup>2</sup>**

<sup>1</sup>Research Scholar, Department of Pharmaceutics, Institute of Pharmacy, Bundelkhand University, Jhansi.

<sup>2</sup>Assistant Professor, Department of Pharmaceutics, Institute of Pharmacy, Bundelkhand University, Jhansi.

Article Received on  
11 June 2023,

Revised on 01 July 2023,  
Accepted on 21 July 2023

DOI: 10.20959/wjpr202313-29150

### **\*Corresponding Author**

**Kunwar Abdul Kalam**

Research Scholar,

Department of

Pharmaceutics, Institute of

Pharmacy, Bundelkhand

University, Jhansi.

### **ABSTRACT**

Sustained release drug delivery systems have emerged as a promising approach to improve therapeutic effectiveness and patient compliance. This review article aims to provide a comprehensive overview of the advancements in sustained release drug delivery systems, focusing on design principles, formulation strategies, and novel approaches. The introduction highlights the background and significance of sustained release drug delivery systems in optimizing therapy for chronic conditions. The objectives of the review article include exploring the factors influencing system design, considering patient-specific considerations and personalized therapy, understanding the duration of therapy and sustained release requirements, and discussing the role of drug characteristics in selecting appropriate delivery systems. The

review delves into the design principles of sustained release drug delivery systems, emphasizing patient-specific considerations and personalized therapy in system design. It discusses the duration of therapy and sustained release requirements, as well as the role of drug characteristics in selecting appropriate delivery systems. Formulation strategies for sustained release are explored, with a focus on matrix-based formulations, the role of polymers in controlling drug release kinetics, the use of excipients and additives for improved sustained release profiles, and novel approaches and technologies in formulation design. The advantages and challenges of matrix-based formulations are discussed, along with the role of polymers in achieving controlled release profiles. Excipients and additives are explored for

their role in enhancing sustained release profiles, and novel approaches such as nanotechnology and 3D printing are highlighted for their potential in personalized medicine. In conclusion, this review article provides a comprehensive overview of the advancements in sustained release drug delivery systems. By considering design principles, formulation strategies, and novel approaches, researchers and practitioners can enhance therapeutic effectiveness, improve patient compliance, and shape the future of sustained release drug delivery.

**KEYWORD:** Sustained release drug delivery systems; Design principles; Formulation strategies; Polymers; Novel approaches.

## INTRODUCTION

The field of pharmaceuticals has witnessed remarkable progress in the development of drug delivery systems that offer sustained, controlled dispersion, and site-specific targeting. These innovative systems have the potential to revolutionize the way medications are administered, leading to improved therapeutic efficacy, patient compliance, and overall treatment outcomes. In this review article, we will explore the recent advancements in sustained release drug delivery systems, focusing on their design principles, formulation strategies, and the impact they have on therapeutic effectiveness.<sup>[1]</sup>

The primary goal of any drug delivery system is to ensure the rapid achievement and subsequent maintenance of therapeutic concentrations of the medication at the intended site of administration within the body. This is particularly important for chronic diseases that require long-term therapy, as maintaining a steady concentration of the drug in the therapeutic range is crucial for optimal therapeutic outcomes. Sustained release drug delivery systems play a vital role in achieving this goal by providing controlled and prolonged distribution of active pharmaceutical ingredients, ensuring sustained therapeutic levels over an extended period.<sup>[1]</sup>

When designing oral sustained release delivery systems, several factors need to be taken into consideration. Patient-specific considerations, such as age, gender, and physiological variations, play a crucial role in determining the optimal delivery system. Additionally, the duration of therapy and the unique characteristics of the drug being administered must be carefully evaluated to determine the most suitable sustained release strategy. These factors, along with the medical condition being treated, collectively influence the design and formulation of the drug delivery system to ensure therapeutic effectiveness.<sup>[2,3]</sup>

Matrix-based formulations have emerged as economically feasible and versatile options for sustained action dosage forms. Matrix tablets, which are designed to release the drug in a controlled manner, offer several advantages. They have a high dose capacity, allowing for the administration of larger drug quantities, and their simple production process makes them cost-effective and readily scalable. Furthermore, matrix tablets can utilize existing infrastructure, making them easily implementable in pharmaceutical manufacturing processes.<sup>[3]</sup>

Formulation strategies play a critical role in achieving sustained release profiles in matrix-based systems. Polymers, such as poly methyl methacrylate (PMMA), polyglycolic acid, and high-performance microcrystalline cellulose (HPMC), are commonly used as matrix materials.

These polymers form a barrier around the drug particles or regulate the diffusion of the drug through the matrix, thereby controlling the rate of drug release. Excipients and additives are carefully selected to optimize the release kinetics and enhance the stability of the formulation. By incorporating innovative approaches and technologies, researchers are continuously striving to improve the drug release kinetics, ensuring a consistent and controlled release of the medication.<sup>[4]</sup>

Manufacturing techniques also play a crucial role in the development of sustained release drug delivery systems. Wet granulation and direct compression methods are commonly employed for matrix-based formulations. These techniques involve the compression of a mixture of the drug, matrix material, and other additives to create tablets with the drug encased within a matrix core. Alternatively, dispersion of solid particles within porous matrices or granulation techniques can be employed to enhance formulation homogeneity and further control drug release. Process optimization and scale-up considerations are essential to ensure consistent and reproducible manufacturing of sustained release systems.<sup>[4,5]</sup>

## Objectives

The primary objective of this review article is to provide an in-depth analysis of the recent advancements in innovative sustained release drug delivery systems. The article aims to:

Explore the design principles involved in the development of sustained release systems, including patient-specific considerations, duration of therapy, and drug characteristics.<sup>[6]</sup>

Discuss the formulation strategies employed in sustained release drug delivery systems, with a focus on matrix-based formulations and the role of polymers, excipients, and additives.<sup>[7]</sup>

Examine the various manufacturing techniques used to produce sustained release systems, including wet granulation, direct compression, and dispersion of solid particles within porous matrices.<sup>[8]</sup>

Review the characterization and evaluation methods employed to assess the drug release kinetics and stability of sustained release systems, both in vitro and in vivo.<sup>[9]</sup>

Investigate the therapeutic applications and clinical outcomes of sustained release drug delivery systems, including their role in chronic disease management, targeted drug delivery, and improved patient compliance.<sup>[10]</sup>

Provide insights into future perspectives and challenges in the field, including emerging trends, nanotechnology integration, regulatory Considerations and Opportunities for personalized medicine.<sup>[11]</sup>

### Scope

The scope of this review article encompasses the advancements in sustained release drug delivery systems, focusing primarily on oral formulations. It includes the design principles, formulation strategies, manufacturing techniques, characterization methods, and therapeutic applications of these systems.<sup>[12]</sup> The review article emphasizes matrix-based formulations due to their economic feasibility and wide applicability. The scope also extends to the evaluation of sustained release systems, including in vitro dissolution testing, in vivo pharmacokinetic studies, stability testing, and regulatory guidelines. Furthermore, the article explores the impact of sustained release systems on therapeutic efficacy, patient outcomes, and the future directions of this field.

It is important to note that while this review article provides a comprehensive overview of the subject matter, it may not cover every aspect or individual research study related to sustained release drug delivery systems.<sup>[13]</sup> The selection of topics and studies included in this review is based on their relevance, significance, and contribution to the advancement of the field.<sup>[14]</sup>

The article aims to provide a consolidated and informative overview of the recent advancements in innovative sustained release drug delivery systems while offering insights into future perspectives and challenges.

## **Design principles of sustained release drug delivery systems**

### ***Factors influencing system design***

The design of a sustained release drug delivery system involves careful consideration of various factors to ensure optimal performance and therapeutic efficacy.<sup>[15]</sup> These factors influence the selection of appropriate materials, formulation strategies, and release kinetics of the system. In this section, we will discuss the key factors that influence the design of sustained release drug delivery systems.<sup>[16]</sup>

### **Medical Condition and Treatment goals**

The nature of the medical condition being treated and the desired treatment goals play a significant role in system design. Different diseases may require specific release profiles, site-specific targeting, or prolonged drug release to achieve therapeutic effectiveness. For example, in the treatment of chronic pain, sustained release systems with controlled drug release over an extended period may be desirable to maintain constant pain relief.<sup>[17]</sup>

### **Patient-Specific considerations**

Patient-specific factors such as age, gender, physiological variations, and individual needs must be taken into account during system design.<sup>[18]</sup> The age of the patient can impact the dosage requirements and the frequency of administration. For pediatric patients or elderly individuals, systems that provide reduced dosing frequency and improved convenience may be preferred. Patient compliance and ease of use are critical considerations to enhance treatment outcomes.<sup>[19]</sup>

### **Duration of therapy**

The duration of therapy influences the design of sustained release systems. Some medical conditions require long-term treatment, while others may necessitate intermittent or pulsatile drug release.<sup>[20]</sup> The release kinetics of the system must be carefully tailored to ensure the sustained presence of the drug at the desired therapeutic levels over the required duration of therapy.<sup>[21]</sup>

### **Drug characteristics**

The physicochemical properties of the drug, such as solubility, stability, and pharmacokinetics, significantly impact the design of sustained release systems.<sup>[22]</sup> Drugs with a short half-life or a narrow therapeutic window may benefit from sustained release formulations to maintain therapeutic levels and minimize fluctuations. The drug's solubility and permeability

characteristics determine the choice of delivery system and the rate of drug release.<sup>[23]</sup>

### **Route of administration**

The route of administration plays a crucial role in system design. Different routes, such as oral, transdermal, or parenteral, have varying requirements for sustained release.<sup>[24]</sup> For instance, oral sustained release systems must withstand the harsh acidic environment of the stomach and provide controlled release in the gastrointestinal tract, whereas transdermal systems should ensure controlled permeation through the skin over an extended period.<sup>[25]</sup>

### **Stability and Shelf life**

The stability and shelf life of the drug and the delivery system are important considerations. Formulation components, such as polymers and excipients, should maintain stability during storage and throughout the intended duration of therapy. The potential for drug degradation, aggregation, or interaction with the delivery system must be evaluated to ensure the system's efficacy over its shelf life.<sup>[26]</sup>

### **Regulatory and Safety considerations**

Regulatory guidelines and safety requirements influence system design. Compliance with regulatory standards for drug release, quality control, and safety is essential. The selection of materials and excipients should adhere to regulatory guidelines, ensuring compatibility, biocompatibility, and absence of toxicity or adverse effects.<sup>[27]</sup>

### **Patient-specific Considerations and Personalized therapy**

Patient-specific considerations and personalized therapy play a pivotal role in the design of sustained release drug delivery systems. Each patient is unique, with individual characteristics and needs that must be taken into account to optimize treatment outcomes.<sup>[28]</sup> By tailoring drug delivery systems to individual patients, personalized therapy can be achieved, leading to improved efficacy, safety, and patient satisfaction. In this section, we will discuss the patient-specific considerations and strategies for personalized therapy in the context of sustained release drug delivery systems.<sup>[29]</sup>

### **Demographic factors**

Demographic factors, such as age, gender, and body weight, are important considerations in personalized therapy. These factors can influence drug metabolism, absorption, and distribution within the body. For example, pediatric patients may require lower doses and modified release

profiles to ensure safety and efficacy. Similarly, gender-based differences in drug pharmacokinetics may necessitate customized release kinetics to achieve optimal therapeutic outcomes.<sup>[30]</sup>

### **Disease Characteristics and Patient response**

The specific characteristics of the medical condition being treated and the patient's response to therapy are crucial in designing personalized sustained release drug delivery systems. Factors such as disease severity, stage, and progression may influence the required drug dose, frequency of administration, and duration of therapy.<sup>[31]</sup> Personalized therapy can involve adapting the release profile to match the patient's needs, ensuring adequate drug exposure to achieve therapeutic efficacy.<sup>[32]</sup>

### **Pharmacogenomics and Genetic variations**

Pharmacogenomics, the study of how an individual's genetic makeup influences drug response, is an emerging field that can inform personalized therapy. Genetic variations in drug-metabolizing enzymes, transporters, or drug targets can impact drug efficacy and toxicity. By considering an individual's genetic profile, personalized sustained release systems can be designed to accommodate variations in drug metabolism and optimize therapeutic outcomes.<sup>[33]</sup>

### **Patient Compliance and Preferences**

Patient compliance is a critical factor in the success of any treatment. Non-adherence to medication regimens can compromise treatment effectiveness. Personalized therapy should take into account patient preferences and lifestyle factors to enhance adherence and treatment satisfaction. Sustained release systems offer advantages such as reduced dosing frequency and convenience, which can improve patient compliance and overall treatment experience.<sup>[34]</sup>

### **Tailoring release kinetics**

Personalized therapy can involve tailoring the release kinetics of the drug delivery system to match the patient's needs. This can be achieved through the selection of appropriate polymers, excipients, and formulation techniques. By modifying the drug release rate, duration, and pulsatile profiles, sustained release systems can be customized to address specific patient requirements, such as fluctuating symptom patterns or time-specific drug administration needs.<sup>[35]</sup>



### **Monitoring and Feedback**

Personalized therapy can benefit from real-time monitoring of drug levels and patient response. This can be achieved through the integration of technologies such as drug sensors, wearable devices, or remote monitoring systems.<sup>[36]</sup> By obtaining feedback on drug efficacy, adverse effects, or therapeutic response, adjustments can be made to the sustained release system to optimize therapy.<sup>[37]</sup>

### **Future Potential: Precision Medicine and Theranostics**

Advancements in precision medicine and theranostics hold immense potential for personalized sustained release therapy. Precision medicine aims to tailor treatment based on an individual's unique molecular characteristics, combining genetic, proteomic, and clinical data.<sup>[37]</sup> Theranostics, on the other hand, involves the integration of diagnostics and therapeutics to optimize treatment outcomes. These approaches can inform the design of personalized sustained release systems, targeting specific molecular markers or disease pathways.<sup>[38]</sup>

### **Duration of Therapy and Sustained release requirements**

The duration of therapy and the specific sustained release requirements are crucial considerations in the design of sustained release drug delivery systems. These factors determine the release kinetics and duration of drug action, ensuring that therapeutic concentrations are maintained over the required period. In this section, we will discuss the importance of considering the duration of therapy and the specific sustained release requirements in the design of drug delivery systems.<sup>[39]</sup>

### **Chronic Conditions and Long-Term Therapy**

For chronic conditions that require long-term therapy, sustained release drug delivery systems offer significant advantages over conventional immediate-release formulations. They provide a continuous and controlled release of the drug, reducing the frequency of dosing and ensuring consistent therapeutic drug levels. By extending the duration of drug action, sustained release systems can improve patient compliance and convenience, minimizing the burden of frequent administration.<sup>[40]</sup>

### **Prolonged drug exposure**

Certain diseases or therapeutic approaches may benefit from prolonged drug exposure.<sup>[41]</sup> In these cases, sustained release systems can be tailored to provide an extended release profile, maintaining drug concentrations within the therapeutic range for an extended duration. This



is particularly important for medications that require a gradual buildup of therapeutic levels or drugs with a prolonged half-life.<sup>[42]</sup>

### **Tailored release profiles**

The duration of therapy and the specific therapeutic goals influence the desired release profiles of sustained release systems. Release profiles can be designed to match the pharmacokinetic and pharmacodynamic requirements of the drug and the disease being treated. For example, diseases with a circadian rhythm, such as asthma or arthritis, may require pulsatile release profiles that align with the peak symptom patterns.<sup>[43]</sup>

### **Disease Progression and Treatment stages**

The stage and progression of the disease impact the sustained release requirements. Different stages of the disease may necessitate different release profiles. In some cases, a more aggressive initial release followed by a sustained release phase may be required to achieve optimal therapeutic outcomes.<sup>[44]</sup> By considering the disease progression and the treatment stages, sustained release systems can be designed to address the evolving needs of the patient.<sup>[45]</sup>

### **Combination Therapy and Sequential release**

Combination therapy, where multiple drugs are administered concurrently, can benefit from sustained release systems that allow for sequential release of the drugs.<sup>[46]</sup> This approach ensures synchronized drug delivery and optimized therapeutic effects. By incorporating multiple drug substances into a single sustained release formulation or using separate formulations with staggered release profiles, combination therapies can be effectively implemented.<sup>[47]</sup>

### **Flexibility and Adjustability**

The duration of therapy and sustained release requirements may vary among patients due to individual differences or changes in treatment regimens.<sup>[48]</sup> Flexibility and adjustability of sustained release systems allow for personalized therapy and adaptation to changing patient needs. Systems that allow for dose adjustments, dose titration, or the ability to switch between sustained release and immediate-release formulations offer increased flexibility in tailoring therapy.<sup>[49]</sup>

### **Patient Convenience and Quality of life**

Sustained release drug delivery systems offer improved patient convenience and quality of life

by reducing the dosing frequency and eliminating the need for multiple administrations throughout the day. Patients can benefit from simplified treatment regimens and improved medication adherence, leading to enhanced treatment outcomes and overall patient satisfaction.<sup>[50]</sup>

### **Drug Characteristics and Selection of appropriate delivery systems**

The characteristics of the drug being delivered play a significant role in the design of sustained release drug delivery systems. The drug's physicochemical properties, such as solubility, stability, and pharmacokinetics, influence the selection of appropriate delivery systems and formulation strategies. In this section, we will discuss the importance of considering drug characteristics and the selection of suitable delivery systems in the design of sustained release formulations.<sup>[51]</sup>

### **Solubility and Permeability**

The solubility and permeability of the drug are crucial factors in determining the suitable delivery system. Poorly soluble drugs may require special formulation techniques, such as solid dispersion or nanoparticle encapsulation, to enhance solubility and enable sustained release. For drugs with low permeability, such as large molecules or peptides, alternative delivery routes or specialized delivery systems may be necessary to achieve sustained release and optimal bioavailability.<sup>[52]</sup>

### **Stability**

The stability of the drug during formulation, storage, and release is essential for sustained release systems. Some drugs may be prone to degradation, hydrolysis, oxidation, or other chemical reactions. In such cases, appropriate formulation strategies, such as the use of protective excipients, stabilizers, or encapsulation techniques, should be employed to maintain drug stability throughout the release period. Stability considerations ensure that the drug remains efficacious and safe over the intended duration of therapy.<sup>[53]</sup>

### **Pharmacokinetics**

Understanding the pharmacokinetic profile of the drug is crucial for designing sustained release systems. Factors such as the drug's half-life, clearance rate, volume of distribution, and therapeutic window influence the selection of appropriate release kinetics and dosage regimens. Drugs with short half-lives may require sustained release systems to maintain therapeutic concentrations over an extended period. Conversely, drugs with long half-lives may

require modifications to achieve appropriate release kinetics and avoid drug accumulation.<sup>[54]</sup>

### **Dose and Release profile**

The desired dose and release profile of the drug influence the selection of appropriate delivery systems. Different diseases or therapeutic goals may require specific release profiles, such as zero-order, first-order, or pulsatile release. The release profile should be tailored to achieve the desired therapeutic effect, whether it is a constant drug concentration for maintenance therapy or a time-specific release for circadian rhythm-based treatments.<sup>[55]</sup>

### **Formulation compatibility**

The compatibility of the drug with various excipients and delivery systems is an important consideration. Some drugs may interact with certain excipients, affecting their stability or release characteristics. It is crucial to select excipients and delivery systems that are compatible with the drug, ensuring that they do not compromise the drug's efficacy, safety, or release profile.<sup>[56]</sup>

### **Route of administration**

The route of administration impacts the selection of appropriate delivery systems. Different routes, such as oral, transdermal, or injectable, have varying requirements for sustained release formulations. For example, oral sustained release systems must withstand the harsh environment of the gastrointestinal tract while providing controlled release, while transdermal systems must facilitate controlled drug permeation through the skin over an extended period. The selection of the most suitable route and delivery system depends on the drug's characteristics and the desired therapeutic outcome.<sup>[57]</sup>

### **Combination therapy**

In cases where combination therapy is employed, the selection of suitable delivery systems becomes more complex. Compatibility between different drugs, their release profiles, and potential drug-drug interactions must be considered. Combination therapies may require separate delivery systems or innovative formulations that allow for simultaneous or sequential release of multiple drugs, ensuring optimal therapeutic effects and minimizing drug-drug interactions.<sup>[58]</sup>

## Formulation strategies for sustained release

### Matrix-based formulations: Advantages and challenges

Matrix-based formulations have gained significant popularity in the development of sustained release drug delivery systems. These formulations utilize a matrix material that encapsulates the drug, controlling its release over time. Matrix-based formulations offer several advantages over other delivery systems, but they also come with their own set of challenges. In this section, we will discuss the advantages and challenges associated with matrix-based formulations in sustained release drug delivery.<sup>[59]</sup>

### Advantages of Matrix-Based Formulations

**Economic feasibility:** Matrix-based formulations are often considered economically feasible due to their simple production process and utilization of existing infrastructure. The manufacturing of matrix tablets involves blending the drug with the matrix material and other excipients, followed by compression into tablet form. This simplicity of production helps in reducing manufacturing costs and enables scalability.<sup>[60]</sup>

**High dose capacity:** Matrix-based formulations offer high dose capacity, allowing for the delivery of larger drug quantities in a single tablet. This is particularly beneficial for drugs that require high doses or for patients who require a significant amount of medication. Matrix tablets can accommodate a higher drug load while maintaining the desired release profile, eliminating the need for multiple tablets or dosing units.<sup>[61]</sup>

**Controlled Release Profile:** Matrix materials in sustained release formulations provide controlled release profiles, ensuring a gradual and sustained release of the drug over an extended period. The matrix acts as a barrier, regulating the diffusion or erosion of the drug, thereby controlling its release kinetics. This controlled release profile helps in maintaining therapeutic drug levels within the desired range, reducing the frequency of dosing and optimizing therapeutic efficacy.<sup>[62]</sup>

**Versatility in formulation design:** Matrix-based formulations offer versatility in the selection of matrix materials, excipients, and additives. Various polymers, such as poly methyl methacrylate (PMMA), polyglycolic acid, or high-performance microcrystalline cellulose (HPMC), can be used as matrix materials, allowing for customization of the release profile. Excipients and additives can be incorporated to further modulate drug release, enhance stability, or improve other formulation properties.<sup>[63]</sup>

Potential for Combination Therapy: Matrix-based formulations provide opportunities for combination therapy, where multiple drugs can be incorporated into a single sustained release formulation. Different drugs can be combined within the matrix, enabling synchronized release profiles and optimized therapeutic effects. This simplifies the dosing regimen, improves patient compliance, and enhances the effectiveness of combination therapies.<sup>[63]</sup>

**Table 1: Comparison of Matrix-based formulations for sustained release drug delivery systems.**

Formulation	Advantages	Challenges	Examples of Polymers	Examples of Excipients
Hydrophilic Matrix	- Simple formulation process	- Potential for burst release	- Hydroxypropyl methylcellulose (HPMC)	- Lactose, microcrystalline cellulose (MCC)
	- Cost-effective production	- Limited control over release kinetics	- Polyethylene oxide (PEO)	- Povidone, sodium carboxymethyl cellulose (NaCMC)
Lipid Matrix	- Enhanced drug solubility for lipophilic drugs	- Risk of lipid oxidation	- Solid lipids (e.g., glycerides)	- Surfactants (e.g., polysorbate 80)
	- Reduced risk of burst release	- Limited drug loading capacity	- Liquid lipids (e.g., oils)	- Fatty acids, cholesterol
pH- Dependent Matrix	- Targeted drug release in specific gastrointestinal regions	- Susceptible to pH variations in the gastrointestinal tract	- Methacrylic acid copolymers (e.g., Eudragit®)	- Plasticizers, pH modifiers
	- Versatile release profiles (e.g., enteric coating)	- Complexity in formulation design	- Cellulose acetate phthalate (CAP)	- Talc, triethyl citrate
Swellable Matrix	- Suitable for highly water-soluble drugs	- Limited control over release rate	- Sodium carboxymethyl cellulose (NaCMC)	- Crosslinkers (e.g., calcium chloride)
	- Ability to modulate release by polymer swelling	- Potential for dose dumping	- Polyethylene glycol (PEG)	- Disintegrants (e.g., croscarmellose sodium)

### Challenges of Matrix-based formulations

**Formulation homogeneity:** Achieving uniform drug distribution throughout the matrix can be challenging. Poor formulation homogeneity may lead to inconsistent drug release and compromised therapeutic efficacy. Granulation techniques, such as wet granulation or solid dispersion, may be required to improve the distribution of the drug within the matrix and

enhance formulation homogeneity.<sup>[65]</sup>

**Burst release:** Matrix-based formulations may be prone to burst release, where an initial release of the drug occurs soon after administration. This burst release can result from drug particles being located closer to the surface of the matrix or from the erosion of the matrix itself. Burst release can lead to rapid drug absorption, potentially causing adverse effects or inadequate therapeutic efficacy.<sup>[66]</sup>

**Limited Control over Release Kinetics:** While matrix-based formulations offer controlled release profiles, achieving precise control over the release kinetics can be challenging. Factors such as the solubility and diffusion properties of the drug, the porosity of the matrix, and the erosion characteristics of the matrix material can influence drug release kinetics. Fine-tuning the formulation to achieve the desired release profile requires careful selection of matrix materials and formulation parameters.<sup>[67]</sup>

**Influence of Environmental Factors:** Environmental factors, such as pH, temperature, and fluid composition, can influence the release kinetics of matrix-based formulations. Variations in these factors within the gastrointestinal tract can impact drug release, affecting the consistency and predictability of the sustained release system. Ensuring robust performance across different physiological conditions is a challenge in the development of matrix-based formulations.<sup>[68]</sup>

**Limited Flexibility in Release Profiles:** Matrix-based formulations may have limitations in achieving complex or customized release profiles. Achieving specific release patterns, such as pulsatile or time-specific release, can be challenging with matrix systems. Innovative formulation strategies or combination approaches may be required to overcome these limitations and achieve more tailored release profiles.<sup>[69]</sup>

### **Role of polymers in controlling drug release kinetics**

Polymers play a critical role in controlling the drug release kinetics in sustained release drug delivery systems. These polymeric materials are incorporated into the formulation to encapsulate or bind the drug, forming a matrix or coating that regulates the release of the drug over time. The selection of appropriate polymers and their characteristics significantly influence the release kinetics of the drug. In this section, we will discuss the role of polymers in controlling drug release kinetics and their impact on sustained release formulations.<sup>[70]</sup>

**Diffusion-Controlled release**

One of the primary mechanisms by which polymers control drug release is diffusion. Polymers with specific properties, such as molecular weight, cross-linking density, or porosity, can regulate the diffusion of the drug molecules through the polymer matrix. Diffusion-controlled release occurs when the drug molecules migrate through the polymer matrix by a concentration gradient. Polymers like ethyl cellulose, polyvinyl alcohol, or cellulose acetate are commonly used for diffusion-controlled release systems.<sup>[71]</sup>

**Erosion-Controlled release**

In erosion-controlled release systems, the polymer matrix undergoes gradual degradation or erosion over time, leading to the release of the encapsulated drug. The degradation or erosion of the polymer matrix can be influenced by factors such as the hydrophilicity, molecular weight, or cross-linking of the polymer. As the matrix erodes, the drug is released from the system. Examples of polymers used in erosion-controlled release include polylactic acid (PLA), polyglycolic acid (PGA), and their copolymers (PLGA).<sup>[72]</sup>

**Swelling-Controlled release**

Swelling-controlled release occurs when the polymer matrix swells upon contact with body fluids, allowing the drug to be released. The degree of swelling of the polymer matrix determines the rate and extent of drug release. Polymers that exhibit swelling properties, such as hydrogels or hydrophilic polymers like polyethylene glycol (PEG) or polyvinyl pyrrolidone (PVP), are commonly employed in swelling-controlled release systems. The swelling behavior of these polymers can be modulated by factors such as polymer composition, cross-linking, or pH sensitivity.<sup>[73]</sup>

**Combination approaches**

In many cases, a combination of diffusion, erosion, and swelling mechanisms may be involved in controlling drug release kinetics. This can be achieved by utilizing polymers with specific properties or by employing a blend of polymers in the formulation. By combining different mechanisms, a more precise control over the release kinetics can be achieved, allowing for customized drug release profiles.<sup>[75]</sup>

**Modulating polymer properties**

The properties of the polymer, such as its molecular weight, hydrophilicity, cross-linking density, or degradation rate, can be modified to control drug release kinetics. Altering these



properties can influence the diffusion rate, erosion rate, or swelling behavior of the polymer matrix, thus affecting the release profile of the drug. By selecting polymers with specific characteristics and adjusting their formulation parameters, the desired sustained release profile can be achieved.<sup>[75]</sup>

### Polymer-Drug compatibility

Another important aspect is the compatibility between the polymer and the drug. Some drugs may interact with the polymer matrix, affecting their release kinetics or stability. It is crucial to select polymers that are compatible with the drug to ensure optimal performance of the sustained release system. Compatibility testing and evaluation should be conducted to ensure the drug's stability, integrity, and desired release kinetics within the selected polymer matrix.<sup>[76]</sup>

### Excipients and Additives for improved sustained release profiles

Excipients and additives play a crucial role in the formulation of sustained release drug delivery systems. They are incorporated into the formulation alongside the active pharmaceutical ingredient (API) and polymers to enhance the sustained release profiles, improve formulation properties, and ensure stability. In this section, we will discuss the role of excipients and additives in achieving improved sustained release profiles.<sup>[77]</sup>




Figure illustrating drug release profiles.<sup>[77]</sup>

### Hydrophilic matrices

Hydrophilic excipients such as hydroxypropyl methylcellulose (HPMC) and sodium carboxymethylcellulose (CMC) are commonly used in sustained release formulations. These excipients form a hydrophilic matrix that swells upon contact with body fluids, resulting in controlled release of the drug. The hydrophilic matrix retards drug diffusion and provides a

sustained release effect.<sup>[78]</sup>

### **Lipid matrices**

Lipid-based excipients, such as waxes, fats, and oils, can be used to create lipid matrices in sustained release formulations. Lipids offer the advantage of prolonged drug release due to their hydrophobic nature, which slows down drug diffusion. The choice of lipid excipient depends on factors such as drug solubility, compatibility, and release requirements.<sup>[79]</sup>

### **pH-Dependent Release modifiers**

Excipients that exhibit pH-dependent solubility can be used to modify drug release profiles in response to changes in pH along the gastrointestinal tract. Examples include enteric polymers like cellulose acetate phthalate (CAP) and methacrylic acid copolymers. These excipients remain insoluble at low pH (e.g., in the stomach) but dissolve or become permeable at higher pH (e.g., in the intestine), allowing for controlled drug release in specific regions of the gastrointestinal tract.<sup>[80]</sup>

### **Release retardants**

Release retardants are excipients that help in achieving sustained drug release by controlling the diffusion of the drug from the matrix. Hydrophilic polymers like HPMC, ethyl cellulose, or polyvinyl alcohol can act as release retardants. These excipients regulate the diffusion of the drug through the matrix, slowing down the release rate and extending the drug's residence time within the formulation.<sup>[81]</sup>

### **Plasticizers**

Plasticizers are additives used to improve the flexibility and mechanical properties of the sustained release matrix. They enhance the deformability and elasticity of the matrix, improving tablet integrity and reducing the risk of cracking or breaking during manufacturing and use. Commonly used plasticizers include polyethylene glycol (PEG), propylene glycol (PG), and glycerol.<sup>[82]</sup>

### **Disintegrants**

In some sustained release formulations, it may be desirable to have a disintegration mechanism to facilitate drug release after a specific lag time. Disintegrants help in breaking down the matrix and promoting drug release. Examples of disintegrants used in sustained release formulations include cross-linked sodium carboxymethylcellulose and croscarmellose

sodium.<sup>[83]</sup>

### **Stabilizers and Antioxidants**

Stabilizers and antioxidants are used to ensure the stability and integrity of the drug and the formulation. These additives protect the drug and other excipients from degradation caused by light, heat, moisture, or oxidation. Examples of stabilizers and antioxidants include ascorbic acid, tocopherols, and sodium metabisulfite.<sup>[84]</sup>

### **Lubricants and Glidants**

Lubricants and glidants are used to improve the flow properties of the formulation during manufacturing, prevent sticking or adhesion to equipment, and facilitate tablet compression. Common lubricants include magnesium stearate, stearic acid, and talc. Glidants, such as colloidal silicon dioxide, help in reducing interparticle friction and improving flowability.<sup>[58]</sup>


### **Other excipients**

Other excipients, such as fillers, binders, and diluents, may be incorporated into sustained release formulations to optimize tablet properties, provide bulk, or aid in the tablet manufacturing process. Examples include lactose, microcrystalline cellulose, and pregelatinized starch.<sup>[86]</sup>

The selection and optimization of excipients and additives depend on the specific drug, release requirements, and formulation considerations. Formulation development involves careful evaluation of compatibility, release kinetics, stability, and other critical parameters to achieve the desired sustained release profiles and ensure the overall quality of the formulation.<sup>[86]</sup>

### **Novel Approaches and Technologies in formulation design**

Formulation design in the field of sustained release drug delivery has witnessed significant advancements with the development of novel approaches and technologies. These innovative strategies aim to overcome challenges associated with conventional formulation methods, enhance drug release profiles, improve therapeutic efficacy, and offer new possibilities for personalized medicine. In this section, we will discuss some of the novel approaches and technologies in formulation design for sustained release drug delivery.<sup>[87]</sup>



Flowchart illustrating formulation design process<sup>[87]</sup>

Table 2: Comparative table of novel Approaches and Technologies in drug delivery systems.

Approach/ Technology	Advantages	Challenges	Applications
Nanotechnology	- Enhanced drug solubility and bioavailability	- Regulatory concerns and safety considerations	- Targeted drug delivery
	- Controlled and sustained release of drugs	- Scale-up and manufacturing challenges	- Gene and siRNA delivery
3D Printing	- Precise control over dosage form design	- Limited material compatibility and formulation options	- Personalized medicine
	- Customization of drug release profiles	- Limited scalability for mass production	- Complex geometries and drug combinations
Implantable Devices	- Prolonged drug release over extended periods	- Invasive implantation procedures	- Chronic disease treatment
	- Localized and targeted drug delivery	- Biocompatibility and foreign body response	- Pain management

Responsive Systems	- On-demand drug release in response to stimuli	- Designing responsive materials with optimal properties	- Treatment of diseases with fluctuating symptoms
	- Tailored release profiles based on specific triggers	- Trigger specificity and responsiveness	- Diabetes management

### Nanotechnology-Based formulations

Nanotechnology has revolutionized the field of drug delivery by offering precise control over drug release and targeting. Nanoparticles, nanocapsules, and nanosuspensions can be engineered to encapsulate drugs and modulate their release kinetics. These nanocarriers can protect the drug from degradation, enhance drug solubility, enable site-specific targeting, and provide sustained release profiles. Additionally, stimuli-responsive nanosystems can release drugs in response to specific triggers such as temperature, pH, or enzymes, allowing for controlled and targeted drug delivery.<sup>[88]</sup>

### Implantable devices

Implantable devices, such as drug-eluting implants or osmotic pumps, offer long-term sustained release of drugs. These devices can be surgically implanted and provide controlled release of drugs over an extended period. Implantable devices are particularly useful for chronic conditions where frequent dosing is impractical or undesirable. They ensure constant drug levels, minimize patient compliance issues, and can be tailored to individual patient needs.<sup>[89]</sup>

### 3D Printing

3D printing technology has gained popularity in the field of drug delivery as a means to fabricate customized dosage forms with controlled release profiles. This technology enables the precise deposition of multiple drug-loaded layers, allowing for the development of complex release patterns and personalized dosage forms. 3D printing offers flexibility in formulation design, enabling the incorporation of different drug combinations, release rates, or even personalized dosing regimens.<sup>[90]</sup>

### Micro- and Nanofluidics

Micro- and nanofluidic devices provide precise control over drug release by manipulating fluid flow at small scales. These devices can create compartmentalized systems or microchannels to control the diffusion or flow of drugs, enabling sustained release profiles. Micro- and

nanofluidics also facilitate the fabrication of high-throughput screening platforms for formulation optimization, allowing for rapid testing and evaluation of various release parameters.<sup>[91]</sup>

### **Hydrogels and Smart polymers**

Hydrogels and smart polymers respond to external stimuli, such as temperature, pH, or light, and can be designed to exhibit specific drug release behavior. These materials can undergo changes in their structure, swelling, or permeability in response to stimuli, leading to controlled drug release. Hydrogels and smart polymers offer the advantage of on-demand or triggered drug release, providing precise temporal control over drug delivery.<sup>[92]</sup>

### **Coating and Encapsulation technologies**

Advanced coating and encapsulation technologies enable the development of sustained release formulations by providing a barrier around the drug, controlling its release rate. Techniques such as microencapsulation, nanoencapsulation, or layer-by-layer assembly can be employed to coat or encapsulate the drug within polymeric shells or particles. These technologies improve drug stability, protect against enzymatic degradation, and provide sustained release profiles.<sup>[93]</sup>

### **Biodegradable matrices**

Biodegradable matrices offer an attractive option for sustained release systems as they can gradually degrade over time, releasing the drug. These matrices can be composed of natural or synthetic polymers that are metabolized or eliminated by the body. Biodegradable matrices eliminate the need for surgical removal, offer controlled and sustained drug release, and minimize the risk of systemic toxicity.

### **Computational Modeling and Simulation**

Computational modeling and simulation techniques play an integral role in formulation design by predicting drug release kinetics, optimizing formulation parameters, and accelerating formulation development. In silico modeling enables the evaluation of various formulation scenarios, release kinetics, and optimization strategies before proceeding to experimental studies. This approach helps to streamline formulation design and reduce time and cost associated with traditional trial-and-error approaches.<sup>[95]</sup>

### Future perspectives

The advancements in sustained release drug delivery systems presented in this review open up promising avenues for future research and development. Several areas offer potential for further exploration and improvement:

**Personalized medicine:** The integration of patient-specific considerations and personalized therapy in sustained release systems holds great promise for tailored treatment regimens. Future research can focus on utilizing advanced technologies, such as nanotechnology and 3D printing, to develop personalized drug delivery systems that meet individual patient needs and optimize therapeutic outcomes.

**Combination therapies:** Sustained release drug delivery systems can be further explored for the delivery of combination therapies, where multiple drugs are released in a controlled and synchronized manner. This approach can be particularly beneficial in the treatment of complex diseases that require multiple therapeutic agents or sequential drug release profiles.<sup>[97]</sup>

**Targeted and Site-Specific Delivery:** Advancements in targeting strategies, such as ligand-mediated targeting, can be integrated into sustained release systems to achieve site-specific drug delivery. Future research can focus on the development of targeted sustained release formulations that deliver drugs specifically to diseased tissues or cells, minimizing off-target effects and improving therapeutic efficacy.

**Integration of responsive systems:** The incorporation of responsive systems, such as stimuli-responsive polymers or smart hydrogels, into sustained release formulations can enable on-demand drug release in response to specific triggers or physiological changes. Future research can explore the potential of these systems to enhance therapeutic outcomes and provide precise temporal control over drug release.

### Challenges

While significant progress has been made in the field of sustained release drug delivery systems, several challenges remain:

**Formulation optimization:** Achieving optimal sustained release profiles requires meticulous formulation optimization. The selection of appropriate polymers, excipients, and additives, as well as the determination of their concentrations and ratios, can be complex. Further research is needed to streamline the formulation optimization process and develop standardized methodologies.



**Regulatory considerations:** The development and commercialization of sustained release systems require compliance with regulatory guidelines and approval processes. Ensuring safety, efficacy, and stability, as well as addressing concerns related to manufacturing scalability and quality control, are critical challenges that need to be addressed.

**Long-term Stability:** Sustained release systems often need to maintain stability over extended periods to ensure consistent drug release. Stability challenges, such as polymer degradation, drug stability, and changes in release kinetics over time, need to be carefully evaluated and addressed to ensure the reliability and efficacy of these systems.

**Translation to clinical practice:** While sustained release drug delivery systems show promise in preclinical studies, translating these technologies to clinical practice can be challenging. Factors such as scalability, cost-effectiveness, ease of administration, and patient acceptance need to be considered for successful clinical implementation.

## CONCLUSION

In conclusion, this review article has provided a comprehensive overview of the advancements in sustained release drug delivery systems, focusing on design principles, formulation strategies, and novel approaches. The field of sustained release drug delivery has witnessed significant progress in optimizing therapy for chronic conditions and improving patient outcomes.

The design principles discussed emphasize the importance of considering patient-specific factors and personalized therapy in the development of sustained release systems. By tailoring therapy to individual patients, it is possible to enhance treatment efficacy and improve patient compliance.

Formulation strategies explored in this review, such as matrix-based formulations, polymer-controlled release, and the use of excipients and additives, offer opportunities to achieve sustained and controlled drug release. These strategies allow for the modulation of drug release kinetics, ensuring optimal therapeutic concentrations over an extended period.

Furthermore, novel approaches and technologies discussed, including nanotechnology, 3D printing, and implantable devices, present exciting possibilities for personalized medicine and precise drug release. These innovative approaches offer enhanced control over drug delivery, enabling tailored treatment regimens and improving patient outcomes.

The advancements in sustained release drug delivery systems presented in this review hold great promise for the future of pharmaceutical sciences. By understanding the design principles, utilizing formulation strategies, and incorporating novel approaches, researchers and practitioners can continue to improve therapeutic effectiveness, enhance patient compliance, and shape the landscape of sustained release drug delivery.

In summary, sustained release drug delivery systems have evolved to address the challenges of optimizing therapy for chronic conditions. The integration of design principles, formulation strategies, and novel approaches paves the way for more effective and personalized treatments, ultimately benefiting patients and advancing the field of drug delivery.

## REFERENCES

1. Prabhu P. Advancements in sustained release drug delivery systems: Design principles, formulation strategies, and novel approaches. *Int J Pharm*, 2020; 587: 119674.
2. Gupta A, Aggarwal G, Singla S, Arora V. Matrix tablets: An overview. *Int J Pharm Sci Drug Res*, 2011; 3(4): 223-229.
3. Pandey A. Polymers used for sustained release formulation: A review. *Indo Am J Pharm Res*, 2013; 3(1): 1-15.
4. Maiti S. Excipients used in sustained release dosage forms: A review. *Int J Appl Pharm*, 2018; 10(2): 1-9.
5. Wang S, Liu R, Fu Y, Kao WJ. Release mechanisms and applications of drug delivery systems for extended-release. *Expert Opinion on Drug Delivery*, 2020; 1, 17(9): 1289-304.
6. Geraili A, Xing M, Mequanint K. Design and fabrication of drug-delivery systems toward adjustable release profiles for personalized treatment. *View*, 2021; 2(5): 20200126.
7. Borandeh S, van Bochove B, Teotia A, Seppälä J. Polymeric drug delivery systems by additive manufacturing. *Advanced drug delivery reviews*, 2021; 1, 173: 349-73.
8. Prakhar A, Akhtar S. A comprehensive review on sustained release matrix tablets: a promising dosage form. *Universal Journal of Pharmaceutical Research*, 2018; 3(6): 49- 54.
9. Ghezzi M, Pescina S, Padula C, Santi P, Del Favero E, Cantù L, Nicoli S. Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. *Journal of Controlled Release*, 2021; 10, 332: 312-36.

10. Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. *International journal of nanomedicine*, 2018; 20: 4727-45.
11. Bodunde OP, Ikumapayi OM, Akinlabi ET, Oladapo BI, Adeoye AO, Fatoba SO. A futuristic insight into a “nano-doctor”: a clinical review on medical diagnosis and devices using nanotechnology. *Materials Today: Proceedings*, 2021; 1, 44: 1144-53.
12. Zaborenko N, Shi Z, Corredor CC, Smith-Goettler BM, Zhang L, Hermans A, Neu CM, Alam MA, Cohen MJ, Lu X, Xiong L. First-principles and empirical approaches to predicting in vitro dissolution for pharmaceutical formulation and process development and for product release testing. *The AAPS journal*, 2019; 21: 1-20.
13. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *Bmj*, 2017; 21: 358.
14. Griffith DA, Tamer Cavusgil S, Xu S. Emerging themes in international business research. *Journal of international business studies*, 2008; 1, 39: 1220-35.
15. Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S. Nano based drug delivery systems: recent developments and future prospects. *Journal of nanobiotechnology*, 2018; 16(1): 1-33.
16. Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schöneich C, Winter G, Friess W, Crommelin DJ, Carpenter JF. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. *Journal of pharmaceutical sciences*, 2012; 1, 101(3): 946-54.
17. Thomas RL, Zubair MY, Hayes B, Ashby MA. Goals of care: a clinical framework for limitation of medical treatment. *Medical Journal of Australia*, 2014; 201(8): 452-5.
18. Wang K, Zhao Y, Chang YH, Qian Z, Zhang C, Wang B, Vannan MA, Wang MJ. Controlling the mechanical behavior of dual-material 3D printed meta-materials for patient-specific tissue-mimicking phantoms. *Materials & Design*, 2016; 15, 90: 704-12.
19. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. *Nature Reviews Drug Discovery*, 2023; 22(5): 387-409.
20. Jain KK. An overview of drug delivery systems. *drug delivery systems*, 2020; 1-54.
21. Bhowmik D, Gopinath H, Kumar BP, Duraivel S, Kumar KS. Controlled release drug

- delivery systems. *The Pharma Innovation*, 2012; 1: 1(10).
22. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. *Acta Pharmaceutica Sinica B*, 2021; 1, 11(8): 2537-64.
  23. Ratnaparkhi MP, Gupta Jyoti P. Sustained release oral drug delivery system-an overview. *Terminology*, 2013; 3(4): 10-22270.
  24. Virmani T, Gupta J. Pharmaceutical application of microspheres: an approach for the treatment of various diseases. *Int J Pharm Sci Res*, 2017; 8(8): 3253-60.
  25. Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. *Journal of Controlled Release*, 2016; 28, 240: 504-26.
  26. Muralidhara BK, Wong M. Critical considerations in the formulation development of parenteral biologic drugs. *Drug Discovery Today*, 2020; 1, 25(3): 574-81.
  27. Mostaghimi A, Antonini MJ, Plana D, Anderson PD, Beller B, Boyer EW, Fannin A, Freake J, Oakley R, Sinha MS, Smith L. Regulatory and safety considerations in deploying a locally fabricated, reusable face shield in a hospital responding to the COVID-19 pandemic. *Med*, 2020; 18, 1(1): 139-51.
  28. Scheetz L, Park KS, Li Q, Lowenstein PR, Castro MG, Schwendeman A, Moon JJ. Engineering patient-specific cancer immunotherapies. *Nature biomedical engineering*, 2019; 3(10): 768-82.
  29. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. *Nature reviews drug discovery*, 2021; 20(2): 101-24.
  30. Teixeira PJ, Silva MN, Coutinho SR, Palmeira AL, Mata J, Vieira PN, Carraça EV, Santos TC, Sardinha LB. Mediators of weight loss and weight loss maintenance in middle-aged women. *Obesity*, 2010; 18(4): 725-35.
  31. Zhang M, Hu W, Cai C, Wu Y, Li J, Dong S. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment. *Materials Today Bio*, 2022; 1, 14: 100223.
  32. Brunet M, Van Gelder T, Åsberg A, Haufröid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. *Therapeutic drug monitoring*, 2019; 1, 41(3): 261-307.
  33. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. *Nature Reviews Genetics*, 2013; 14(1): 23-34.

34. Varadarajulu S, Petruff C, Ramsey WH. Patient preferences for gender of endoscopists. *Gastrointestinal endoscopy*, 2002; 1, 56(2): 170-3.
35. Javierre E, García SJ, Mol JM, Vermolen FJ, Vuik C, Van Der Zwaag S. Tailoring the release of encapsulated corrosion inhibitors from damaged coatings: controlled release kinetics by overlapping diffusion fronts. *Progress in Organic Coatings*, 2012; 1, 75(1-2): 20-7.
36. Teymourian H, Parrilla M, Sempionatto JR, Montiel NF, Barfidokht A, Van Echelpoel R, De Wael K, Wang J. Wearable electrochemical sensors for the monitoring and screening of drugs. *ACS sensors*, 2020; 21, 5(9): 2679-700.
37. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: An updated review. *International journal of pharmaceutical investigation*, 2012; 2(1): 2.
38. Keek SA, Leijenaar RT, Jochems A, Woodruff HC. A review on radiomics and the future of theranostics for patient selection in precision medicine. *The British journal of radiology*, 2018; 91(1091): 20170926.
39. Cao Y, Samy KE, Bernards DA, Desai TA. Recent advances in intraocular sustained-release drug delivery devices. *Drug discovery today*, 2019; 1, 24(8): 1694-700.
40. Graham CD, Gouick J, Krahé C, Gillanders D. A systematic review of the use of Acceptance and Commitment Therapy (ACT) in chronic disease and long-term conditions. *Clinical psychology review*, 2016; 1, 46: 46-58.
41. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. *Gastroenterology*, 2017; 1, 152(2): 327-39.
42. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences*, 2002; 29, 357(1420): 505-19.
43. Kumar KS, Bhowmik D, Srivastava S, Paswan S, Dutta AS. Sustained release drug delivery system potential. *The pharma innovation*, 2012; 1, 1(2).
44. Lu CH, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1G93A mice that model ALS. *PLoS One*, 2012; 16, 7(7): e40998.
45. Tottoli EM, Dorati R, Genta I, Chiesa E, Pisani S, Conti B. Skin wound healing process and new emerging technologies for skin wound care and regeneration. *Pharmaceutics*, 2020; 12(8): 735.

46. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, Kabanov AV, Batrakova EV. Exosomes as drug delivery vehicles for Parkinson's disease therapy. *Journal of controlled release*, 2015; 10, 207: 18-30.
47. Spring BQ, Bryan Sears R, Zheng LZ, Mai Z, Watanabe R, Sherwood ME, Schoenfeld DA, Pogue BW, Pereira SP, Villa E, Hasan T. A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. *Nature nanotechnology*, 2016; 11(4): 378-87.
48. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*, 2008; 49(7): 1239-76.
49. El Aita I, Ponsar H, Quodbach J. A critical review on 3D-printed dosage forms. *Current pharmaceutical design*, 2018; 1, 24(42): 4957-78.
50. Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference?. *Pharmacoeconomics*, 2016; 34: 645-9.
51. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. *International journal of nanomedicine*, 2017; 5: 7291-309.
52. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. *The AAPS journal*, 2009; 11: 740-6.
53. Polizzi KM, Bommarius AS, Broering JM, Chaparro-Riggers JF. Stability of biocatalysts. *Current opinion in chemical biology*, 2007; 1, 11(2): 220-5.
54. Kuhl H. Pharmacokinetics of oestrogens and progestogens. *Maturitas*, 1990; 1, 12(3): 171-97.
55. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. *Fertility and sterility*, 2012; 1, 97(3): 616-22.
56. Jarray A, Gerbaud V, Hemati M. Polymer-plasticizer compatibility during coating formulation: A multi-scale investigation. *Progress in Organic Coatings*, 2016; 1, 101: 195-206.
57. Rowland M. Influence of route of administration on drug availability. *Journal of pharmaceutical sciences*, 1972; 1, 61(1): 70-4.

58. Li J, Wang Y, Zhu Y, Oupický D. Recent advances in delivery of drug–nucleic acid combinations for cancer treatment. *Journal of controlled release*, 2013; 10, 172(2): 589-600.
59. Banerjee S, Pillai J. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs. *Expert opinion on drug metabolism & toxicology*, 2019; 3, 15(6): 499-515.
60. Molinos-Senante M, Hernández-Sancho F, Sala-Garrido R. Economic feasibility study for wastewater treatment: A cost–benefit analysis. *Science of the Total Environment*, 2010; 15, 408(20): 4396-402.
61. He Z, Wan X, Schulz A, Bludau H, Dobrovolskaia MA, Stern ST, Montgomery SA, Yuan H, Li Z, Alakhova D, Sokolsky M. A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. *Biomaterials*, 2016; 1, 101: 296-309.
62. Jamaledin R, Makvandi P, Yiu CK, Agarwal T, Vecchione R, Sun W, Maiti TK, Tay FR, Netti PA. Engineered microneedle patches for controlled release of active compounds: recent advances in release profile tuning. *Advanced Therapeutics*, 2020; 3(12): 2000171.
63. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. *Vaccine*, 2012; 16, 30(13): 2256-72.
64. Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. *Frontiers in oncology*, 2018; 29, 8: 92.
65. Abaci A, Guvendiren M. Designing decellularized extracellular matrix-based bioinks for 3D bioprinting. *Advanced healthcare materials*, 2020; 9(24): 2000734.
66. Yoo J, Won YY. Phenomenology of the initial burst release of drugs from PLGA microparticles. *ACS Biomaterials Science & Engineering*, 2020; 9, 6(11): 6053-62.
67. Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. *Expert opinion on drug delivery*, 2010; 1, 7(4): 429-44.
68. Casson S, Gray JE. Influence of environmental factors on stomatal development. *New phytologist*, 2008; 178(1): 9-23.
69. Huang WC, Hu SH, Liu KH, Chen SY, Liu DM. A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs. *Journal of Controlled Release*, 2009; 3, 139(3): 221-8.



70. Berklund C, Kipper MJ, Narasimhan B, Kim KK, Pack DW. Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres. *Journal of Controlled Release*, 2004; 8, 94(1): 129-41.
71. Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. *Journal of controlled release*, 2012; 20, 161(2): 351-62.
72. Mönkäre J, Hakala RA, Vlasova MA, Huotari A, Kilpeläinen M, Kiviniemi A, Meretoja V, Herzig KH, Korhonen H, Seppälä JV, Järvinen K. Biocompatible photocrosslinked poly (ester anhydride) based on functionalized poly ( $\epsilon$ -caprolactone) prepolymer shows surface erosion controlled drug release in vitro and in vivo. *Journal of controlled release*, 2010; 15, 146(3): 349-55.
73. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. *Advanced Drug Delivery Reviews*, 1993; 1, 11(1-2): 37-57.
74. Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. *Trends in biotechnology*, 2013; 1, 31(3): 177-84.
75. Wu W, Liu B. Modulating the optical properties and functions of organic molecules through polymerization. *Materials Horizons*, 2022; 9(1): 99-111.
76. Liu J, Xiao Y, Allen C. Polymer–drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. *Journal of pharmaceutical sciences*, 2004; 1, 93(1): 132-43.
77. Dürig T, Fassihi R. Guar-based monolithic matrix systems: effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. *Journal of controlled release*, 2002; 23, 80(1-3): 45-56.
78. Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. *Journal of controlled release*, 2011; 25, 154(1): 2-19.
79. Rosiaux Y, Jannin V, Hughes S, Marchaud D. Solid lipid excipients—matrix agents for sustained drug delivery. *Journal of Controlled Release*, 2014; 28, 188: 18-30.
80. Taniguchi C, Kawabata Y, Wada K, Yamada S, Onoue S. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility. *Expert opinion on drug delivery*, 2014; 1, 11(4): 505-16.
81. Hirschler MM. Flame retardants and heat release: review of data on individual polymers. *Fire and Materials*, 2015; 39(3): 232-58.
82. Ghosal K, Chandra A, Roy S, Agatemor C, Thomas S, Provaznik I. Electrospinning over solvent casting: tuning of mechanical properties of membranes. *Scientific reports*, 2018;

- 22, 8(1): 5058.
83. Wang S, Liu R, Fu Y, Kao WJ. Release mechanisms and applications of drug delivery systems for extended-release. *Expert Opinion on Drug Delivery*, 2020; 1, 17(9): 1289-304.
84. Rani M, Shim WJ, Han GM, Jang M, Song YK, Hong SH. Benzotriazole-type ultraviolet stabilizers and antioxidants in plastic marine debris and their new products. *Science of The Total Environment*, 2017; 1, 579: 745-54.
85. Pingali K, Mendez R, Lewis D, Michniak-Kohn B, Cuitino A, Muzzio F. Mixing order of glidant and lubricant—influence on powder and tablet properties. *International journal of pharmaceutics*, 2011; 16, 409(1-2): 269-77.
86. Chaerunisaa AY, Sriwidodo S, Abdassah M. Microcrystalline cellulose as pharmaceutical excipient. In *Pharmaceutical formulation design-recent practices*, 2019; 19. IntechOpen.
87. Yang B, Gomes Dos Santos A, Puri S, Bak A, Zhou L. The industrial design, translation, and development strategies for long-acting peptide delivery. *Expert Opinion on Drug Delivery*, 2022; 3, 19(10): 1233-45.
88. Yellepeddi VK, Joseph A, Nance E. Pharmacokinetics of nanotechnology-based formulations in pediatric populations. *Advanced drug delivery reviews*, 2019; 1, 151: 44-55.
89. Kleiner LW, Wright JC, Wang Y. Evolution of implantable and insertable drug delivery systems. *Journal of controlled release*, 2014; 10, 181: 1-0.
90. Kotta S, Nair A, Alsabeelah N. 3D printing technology in drug delivery: recent progress and application. *Current pharmaceutical design*, 2018; 1, 24(42): 5039-48.
91. Tegenfeldt JO, Prinz C, Cao H, Huang RL, Austin RH, Chou SY, Cox EC, Sturm JC. Micro- and nanofluidics for DNA analysis. *Analytical and bioanalytical chemistry*, 2004; 378: 1678-92.
92. Kalia S, editor. *Polymeric hydrogels as smart biomaterials*. Cham: Springer, 2016.
93. Saleh K, Guigon P. Coating and encapsulation processes in powder technology. In *Handbook of powder technology*, 2007; 1, 11: 323 - 375. Elsevier Science BV.
94. Jha K, Kataria R, Verma J, Pradhan S. Potential biodegradable matrices and fiber treatment for green composites: A review. *AIMS Materials Science*, 2019; 6(1): 119-38.
95. Yan LT, Xie XM. Computational modeling and simulation of nanoparticle self-assembly in polymeric systems: Structures, properties and external field effects. *Progress in Polymer Science*, 2013; 1, 38(2): 369-405.